Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia

• Kathy L. McGraw,
• Johnny Nguyen,
• Rami S. Komrokji,
• David Sallman,
• Najla H. Al Ali,
• Eric Padron,
• Jeffrey E. Lancet,
• Lynn C. Moscinski,
• Alan F. List,
• Ling Zhang

Affiliations

Kathy L. McGraw

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

Johnny Nguyen

Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

Rami S. Komrokji

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

David Sallman

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

Najla H. Al Ali

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

Eric Padron

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

Jeffrey E. Lancet

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

Lynn C. Moscinski

Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

Alan F. List

Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

Ling Zhang

Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA